Cidara Therapeutics Initiates Phase 2b NAVIGATE Trial for CD388 Influenza Prophylaxis

Details

announced the start of its Phase 2b NAVIGATE trial to assess the efficacy and safety of CD388 as a pre-exposure prophylaxis for influenza. The trial, targeting 5,000 healthy unvaccinated adult subjects, will evaluate CD388's potential to prevent influenza during the current flu season. Subjects will receive either CD388 or placebo, with outcomes to be monitored through the remainder of the influenza season.

Items reported

About Cidara Therapeutics Inc.

Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.